Objective To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6-17, and >= 18 years old, treated in a real-world setting. Methods Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP)

An Examination of the Efficacy and Safety of Fenfluramine in Adults, Children, and Adolescents with Dravet Syndrome in a Real-World Practice Setting: A report from the Fenfluramine European Early Access Program / Renzo Guerrini , Nicola Specchio , Ángel Aledo-Serrano , Milka Pringsheim , Francesca Darra , Thomas Mayer , Antonio Gil-Nagel , Tilman Polster , Sameer M Zuberi , Amélie Lothe , Arnold Gammaitoni , Adam Strzelczyk. - In: EPILEPSIA OPEN. - ISSN 2470-9239. - ELETTRONICO. - (2022), pp. 0-0. [10.1002/epi4.12624]

An Examination of the Efficacy and Safety of Fenfluramine in Adults, Children, and Adolescents with Dravet Syndrome in a Real-World Practice Setting: A report from the Fenfluramine European Early Access Program

Renzo Guerrini;
2022

Abstract

Objective To examine the efficacy and safety of fenfluramine in patients with Dravet syndrome (DS) in three age groups: <6, 6-17, and >= 18 years old, treated in a real-world setting. Methods Patients with DS were treated with fenfluramine in the European Union Early Access Program (EAP)
0
0
Renzo Guerrini , Nicola Specchio , Ángel Aledo-Serrano , Milka Pringsheim , Francesca Darra , Thomas Mayer , Antonio Gil-Nagel , Tilman Polster , Sameer M Zuberi , Amélie Lothe , Arnold Gammaitoni , Adam Strzelczyk
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1280968
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 1
social impact